

AD-A116 102


ARMY INST OF DENTAL RESEARCH WASHINGTON DC
A PRELIMINARY REPORT ON THE OSTEOPENIC POTENTIAL OF A BIODEGRAD--ETC(U)
JUN 82 J O HOLLINGER

F/G 6/5


UNCLASSIFIED

NL

100
100



END
DATE
FILMED
8 82
DTIC



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS 1963-A

AD A116102

BIB FILE COPY

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
	AD-A116102	702
4. TITLE (and Subtitle) A Preliminary Report on the Osteogenic Potential of a Biodegradable Copolymer of Polylactide: Polyglycolide (PLA:PGA)		5. TYPE OF REPORT & PERIOD COVERED Manuscript for Publication July - December 1981
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) Jeffrey O. Hollinger		CONTRACT OR GRANT NUMBER(s)
		REVISED: 22 JUNE 1982
9. PERFORMING ORGANIZATION NAME AND ADDRESS U. S. Army Institute of Dental Research Walter Reed Army Medical Center Washington, DC 20012		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS OB 6037, 3S16102BS10, 04, 09
11. CONTROLLING OFFICE NAME AND ADDRESS U. S. Army Medical Research & Development Command SGRD-RMS Fort Detrick, Maryland 21701		12. REPORT DATE 3 December 1981
		13. NUMBER OF PAGES 12
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		15. SECURITY CLASS. (of this report) UNCLASSIFIED
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) This document has been approved for public release and sale; its distribution is unlimited.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES None		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) Biodegradable Copolymer; Polylactic and Polyglycolic Acids; Osteogenic; Osseous Wound Repair; Accelerated Bony Healing.		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) A biodegradable copolymer of 50:50 polylactide:polyglycolide was prepared for implantation into experimentally created osseous defects in the tibias of 25 rats. Similarly prepared defects were made in the humeri and these did not receive copolymer implants. At 7, 14, 21, 28, and 42 days five animals were sacrificed and the implant and untreated sites were evaluated by gross visual inspection and by histologic examination using a Zeiss Videoplan Image Analysis System with Osteoplan for the quantitation of bone morphometrics. When compared with bony defects that were not treated with the biodegradable copolymer implant		

DD FORM 1473 1 JAN 73 EDITION OF 1 NOV 65 IS OBSOLETE

82 06 25 028

UNCLASSIFIED
SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)

BLOCK 20. (continued)

the implant sites displayed a slightly accelerated healing response rate at 7 days ($p < 0.01$), a slightly accelerated response rate at 14 and 21 days ($p < 0.005$), and a similar healing response rate at 28 and 42 days ($p < 0.01$). The copolymer was highly tissue tolerant throughout the period of the investigation.

SECURITY CLASSIFICATION OF THIS PAGE(When Data Entered)

JEFFREY O. HOLLINGER, D.D.S.

DTIC
COPY
INSPECTED
2

Accession For

NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

A PRELIMINARY REPORT ON THE OSTEOGENIC POTENTIAL OF A BIODEGRADABLE
COPOLYMER OF POLYLACTIDE:POLYGLYCOLIDE

SYNOPSIS

A biodegradable copolymer of 50:50 polylactide:polyglycolide was prepared for implantation into experimentally created osseous defects in the tibias of 25 rats. Similarly prepared defects were made in the humeri of the same rats and these defects did not receive copolymer implants. Upon sacrifice, both the implant treated and untreated sites of the experimentally produced osseous defects were evaluated by gross appearance and by histomorphometric examination using a Zeiss Videoplan Image Analysis System with Osteoplan™ (vers 4.1). The animals were evaluated in groups of five at 7, 14, 21, 28, and 42 days. When compared with bony defects that were not treated with the biocompatible, biodegradable copolymer implant, the implant sites displayed an accelerated rate of healing at 7, 14, 21, and 28 days ($p < 0.001$). However, a similar healing response rate was observed at 42 days ($p < 0.25-0.1$). No adverse host tissue responses were observed histologically.

KEY WORDS Biodegradable Copolymer; Polylactic and Polyglycolic Acids; Osteogenic; Osseous Wound Repair; Accelerated Bony Healing.

INTRODUCTION

The alpha-polyesters, polylactide and polyglycolide, have been investigated for use as suture and implant materials for the repair of a variety of soft tissue and osseous wounds.¹⁻⁷ Implanted polymers and copolymers of polylactide and polyglycolide were expected to function in a supportive role, to undergo hydrolytic scission to form nontoxic, excretable metabolites, and to be ultimately replaced by the host's contiguous tissue. Getter⁴ observed that a homopolymer of lactic acid, when used in dogs for mandibular fracture repair, had partially degraded after six weeks and was completely resorbed after thirty-two weeks with the fracture sites being indistinguishable from the adjacent bone areas. Cutright⁵ employed a similar homopolymer implant for the repair of blowout fractures of the orbital floor in monkeys. After thirty-eight weeks it was found that the implants were being tolerated well but had not been completely resorbed, although phagocytosis of polymer fragments was occurring. At this time there is no information in the literature about the osteogenic potential of a 50:50 copolymer of polylactide:polyglycol (PLA:PGA) to induce bony wound healing. It was the purpose of this study, therefore, to evaluate the healing capacity of prepared osseous wounds treated with the biocompatible, biodegradable copolymer of 50:50 PLA:PGA compared with nontreated control bony wounds.

METHODS AND MATERIALS

A commercially synthesized copolymer of 50:50 PLA:PGA (50:50 poly (L (-) lactide co-glycolide), having a viscosity of 0.92 dl/g

as measured in hexafluoroisopropanol at 30C, corresponding to a weight-average-molecular weight of approximately 80,000 Daltons, was solubilized in methylene chloride at a 1:12.5 weight:volume ratio. Anhydrous methanol (1:1) was added to this liquid suspension to precipitate a milky-white gelatinous mass which was then placed into prepared wells (2.0 mm X 1.25 mm) in a Teflon mold. The viscous, milky-white copolymer mass was gently forced into the prepared wells using a supple Teflon spatula and then was placed in a lyophilizer chamber at 30C and a pressure of 0.005 mm of mercury for 48 hours. After 48 hours each copolymer preparation was designated as an implant plug (Figure 0A and 0B) and all plugs were sterilized in ethylene oxide and stored in a dessicator.

Using sodium pentobarbital, USP (Pentobarbital Sodium), 25 adult Walter Reed strain of rats (random male and female) were anesthetized by IP injection at a dose of 3 to 5 mg/100 mg of body weight. Each tibia was prepared for a copolymer implant and each humerus was prepared as a control. The areas over the tibias and the humeri were shaved and scrubbed with povidone iodine, NF (Beta-dine®) for three to five minutes. An incision 1 cm in length was made on the anteriolateral surface of each tibia and humerus and soft tissue was reflected down to bone to expose the broadest area of the diaphysis. A hole was made completely through the cortical plate and into the medullary cavity using a bone trephine (OD = 1.95 mm) and sterile water coolant. An implant was placed in each tibia and

the humeri holes were left void to serve as controls. In this laboratory, histomorphometric evaluation of osseous healing rates of bony wounds in rat tibias and humeri did not reveal any significant differences in the rate of osseous repair. All surgical sites were appropriately sutured and the animals were returned to their individually marked cages. At 7, 14, 21, 28, and 42 days five animals were sacrificed by administration of an overdose of sodium pentobarbital. Gross examination was made of the implant and control areas after surgical removal of the overlying soft tissues. A bone saw was then used to remove the implant and control sites from the contiguous bone and at least 5 mm of host bone remained to encompass these zones. The retrieved specimens were fixed in 10% formalin. After decalcification for 18 hours in Bankuthy's medium, the specimens were prepared for hematoxylin and eosin staining.

Using bright field illumination and polarization microscopy⁸ at a magnification of 200X, histomorphometric analysis was performed on a minimum of 100 histologic fields from both of the experimental (implant) and control sites from each animal. Therefore, a minimum of 200 fields for experimental and control areas were evaluated for each animal. Data from these evaluations from the five rats from each temporal group were combined and the pooled mean values \pm standard deviations were calculated. A Student's t test ($t = \frac{\bar{x}_1 - \bar{x}_2}{\sqrt{\frac{s_1^2 + s_2^2}{n-1}}}$) was performed between the same histomorphometric variables of the same temporal group. The level of significance was determined based upon each t value.

RESULTS

Gross Examination

Control Sites

1. 7 to 14 days: Inspection revealed circular wounds that appeared to be filled with a reddish-brown soft tissue.
2. 21 days: Wounds were similar in configuration to the 7 and 14 day levels, with the exception that tissue in the wound bed appeared to be speckled with osteoid or osseous components.
3. 28 and 42 days: By 28 days it had become increasingly difficult to discern wound sites from contiguous bone. By 42 days all control wounds demonstrated complete osseous union.

Implant Sites

1. 7 days: Rather than the crisply shaped circular implant plug, an irregularly contoured implant was evident in the experimental site. The implant appeared to be firmly fixed in all the experimental sites. Reddish-brown soft tissue was apparent among the implant interstices.
2. 14 through 28 days: It became obvious as the experiment progressed that the copolymer implant was gradually hydrolyzing (breaking down) and that a whitish (osteoid?) tissue fill was filling the prepared wound zones. The implant remained firmly entrenched within the wound bed at all times.
3. 42 days: There appeared to be no gross evidence of the copolymer implant. Bony union appeared to have been achieved.

Histologic Examination

Control Sites

Histologic observation of the healing control sites revealed an unremarkable progression of normal endochondral bone formation. A typical callus developed and osteogenic cell proliferation resulted in a distinct collar of uniting tissue around the defect border. The more rapidly growing areas of the callus displayed chondrocytic differentiation at the early stages (7 through 21 days). As a capillary network developed and became steadily more advanced, vascular penetration into the cartilaginous sanctum occurred and osteoblastic cell populations became predominant. By 28 to 42 days numerous zones of osteoid and bony spicules had been replaced by rapidly coalescing trabeculae (Fig. 1). By 42 days a complete bony union had been achieved, albeit areas of immature bone were evident. Osteons were not present, indicating that at 42 days substantial union was still lacking.

Implant Sites

1. 7 days: The implant appeared as a wavy, heterogenous, and amorphous structure with infrequent lymphocytic infiltrate and a few polymorphonuclear cells (Fig. 2A). Host-cell activity was evident at the implant periphery; centrally, a minimal number of lymphocytes were observed. Juxtaposed to the copolymer implant-host bone boundary were zones of osteoid with frequent robust osteoblasts (Fig. 2B).
2. 14 and 21 days: The implants became increasingly more tenuous as the experiment continued. Observed at 14 days, and more dramatically apparent at 21 days, was the gradual

dissolution of the implant into multiple islands and peninsulas of material with osteoid-immature bone-copolymer intercalations (Fig. 3). Trabeculae with rimming osteoblasts became more predominant at 21 days than at 14 days (Fig. 4). Birefringence of the polyglycolide from hydrolytic scission of the implant was typical of the 21-day histologic picture. A robust periosteal callus was routinely seen by 21 days. Some specimens (Fig. 5) displayed remarkable fervor in their bony healing response.

3. 28 and 42 days: Implant copolymer was present at 42 days in the form of isolated, irregularly shaped small zones of birefringence. Osteoid and trabecular coalescence were evident at 28 and 42 days, despite remaining implant that had not been fully degraded. Capillary penetration and phagocytic cells were often closely associated with residual copolymer islands. Satisfactory callus formation resulted in complete obliteration of the wound defect by 42 days, and in several specimens this result was achieved at the 28-day level (Fig. 6). There was no indication of an inflammatory response in any of the implant specimens. Tissue tolerance of the implant copolymer was extremely favorable.

Histomorphometric Analysis

Using Student's *t* test there was a significant difference in the

pooled mean values between the same histomorphometric variables of the experimental and control sites for the 7, 14, 21, and 28 day temporal groups ($p < 0.001$, or $p < 0.03$ and 0.02 where noted in Table 1). At 42 days the pooled mean values for the same experimental and control variables tended to converge, with real differences diminishing. The level of significance varied from $p < 0.1-0.25$, except as otherwise noted in Table 1. Standard deviations did not vary significantly throughout the experiment (Table 1).

DISCUSSION

In different experiments, Getter *et al.*⁴ and Cutright *et al.*⁵ determined that a homopolymer of lactic acid (PLA) could be used for selected types of osseous wound repair. These investigators also noted that PLA was observed histologically up to 38 weeks after implantation.⁴ Several studies have shown histological evidence of homopolymers of glycolic acid (PGA) being present in soft tissue, varying from 50 to 120 days after implantation.^{2,3} In a histologic study to plot copolymer and homopolymer degradation of PGA and PLA, Cutright *et al.*⁵ determined that by varying the proportions of PLA to PGA, degradation rates could be varied from between 100 days to greater than 220 days. It was found that the homopolymers, PLA and PGA, persisted for the greatest time span, while the 25% PLA degraded most rapidly, followed in succession by 50% and 75% PLA.

Kulkarni *et al.*¹⁰ investigated polylactide degradation *in vivo* using ¹⁴C-labeled homopolymer. These workers compared the kinetics of degradation of the D,L- and L(-)-polymers and they established

that the D,L form degraded more rapidly. This property may be attributed to the high order of crystallinity of this form of polymer. The mechanical properties of homopolymers and copolymers of glycolide and lactide also vary directly with composition. The composition varies, according to Sinclair and Gynn, in relation to the degree of crystallinity.¹¹ The different optical activities (crystallinity) of the homopolymer/copolymer implants could logically explain the variable rates of degradation that have been reported. The degradation rate of a homopolymer/copolymer must be defined in terms of the polymer's optical activity. In the investigation undertaken in this laboratory, a 50:50 poly (L (-) lactide co-glycolide) implant was employed. Beginning at 7 days, and continuing until the experiment was terminated at 42 days, a haphazard breakdown was noted histologically. This observation could contrast markedly with a copolymer of a different optical activity or crystallinity. It is perhaps this factor that has led to some amount of disparity between studies, in terms of degradation rates of copolymers and homopolymers of lactides and glycolides. Also, different preparation techniques for fabrication of the copolymer implant could produce a variety of different physical properties. In this laboratory, a nondeformable, spongy morphology was achieved (Fig. 0A and 0B). In contrast, a glassy, dense structure could have been produced if such an attribute was desired. A hard, spongy architecture allows for rigid, stable bone fixation and permits host access to a vast molecular domain for hydrolytic scission and subsequent hard tissue ingress.

It would be germane at this time to mention briefly the manner by which the 50:50 PLA:PGA copolymer implant is degraded. Nonspecific hydrolytic scission of the copolymer chain results in the generation of lactic acid and glycolic acid residues. The lactic acid becomes incorporated into the tricarboxylic acid cycle and is consequently excreted by the lungs as CO_2 . The glycolic acid molecules are acted upon by glycolate oxidase and are transformed into glyoxylate, which reacts with glycine transaminase and results in the formation of glycine. The glycine can be used for protein synthesis or for the synthesis of serine, which may be employed in the tricarboxylic acid cycle after transformation into pyruvate.

As copolymer dissolution by hydrolytic scission occurred, trabeculae replaced the degrading copolymer. The elements of bone formation or osseous repair that were histomorphometrically analyzed were observed to be in greater abundance and were present earlier in osseous wound sites treated with 50:50 PLA:PGA as compared with untreated control sites. It may be conjectured that the implant degradation products engendered an early osseous inductive response from the pluripotential cells of the cambial layer of the periosteum and endosteum. By 42 days, however, the rate at which bony repair took place in control wounds proceeded at a pace virtually equivalent to the experimental sites. Either the bone-inducing effect of the implant had diminished by 42 days, or the natural healing capacity of the animal had achieved parity with the implant site.

The presence of 50:50 PLA:PGA copolymer did not appear to adversely affect bone wound repair. There was evidence that the rate of early (7-28 days) osseous healing was actually accelerated. This compelling response will be further pursued in the laboratory because a copolymer employed for fracture fixation or for repair of bony discontinuity defects that could degrade in harmony with normal osseous healing would be ideal. If that same copolymer could also orchestrate an accelerated bone reparative process, than this would be superb.

CONCLUSION

Bone healing rate was assessed using selective morphometric variables that were quantitated using a Zeiss Image Analysis System with Osteoplan™ (vers 4.1). When compared with untreated bony wounds, the bony wounds where copolymer implants were inserted displayed an accelerated rate of bone healing at 7, 14, 21, and 28 days ($p < 0.001$); however, a similar healing rate was observed at 42 days ($p < 0.25-0.1$). Histologic evaluation did not indicate that there was any adverse host tissue response to the implant. Because stability in bony wound healing is a critical factor for successful bony repair, a biocompatible, biodegradable therapeutic agent that could hasten early osseous healing could mitigate against fragment migration and the sequella of nonunion.

In conducting the research described in this report, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals" as promulgated by the Committee on the Guide for Laboratory

Animal Facilities and Care, of the Institute of Laboratory Animal Resources, National Academy of Sciences, National Research Council.

Commercial materials and equipment are identified in this report to specify the investigative procedures. Such identification does not imply recommendation or endorsement or that the materials and equipment are necessarily the best available for the purpose. Furthermore, the opinions expressed herein are those of the author and are not to be construed as those of the U. S. Army Medical Department.

TABLE 1. HISTOMORPHOMETRIC ANALYSIS

Pooled $\bar{x} \pm s$	7		14		21		28		42		42	
	Days	Experimental	Control	Days	Experimental	Control	Days	Experimental	Control	Days	Experimental	Control
VV _P	1.2±2.2	0.3±0.9	3.2±3.7	0.6±1.2	3.5±2.8	1.5±2.1	4.1±5.1	2.8±4.1	5.3±3.6	4.7±2.9	4.1±5.1	2.8±4.1
SV _P	23.1±31.2	12.1±3.9	37.2±28.1	13.1±8.7	46.1±47.7	19.2±16.3	48.1±31.7	17.2±19.1	37.2±20.1	43.2±40.1	48.1±31.7	17.2±19.1
D-TRAB _P	11.2±9.3	10.1±11.1	14.2±10.8	9.2±4.7	17.3±15.1	11.3±11.1	15.3±10.6	10.1±8.7	16.3±9.2	15.1±13.9	15.3±10.6	10.1±8.7
SV-UB _P	22.3±18.1	9.2±3.5	31.3±21.2	9.9±7.2	46.2±39.2	18.7±9.9	45.1±31.6	23.2±19.8	53.3±48.0	44.3±39.2	45.1±31.6	23.2±19.8
OB1 _P	5.2±2.1	1.2±0.5	12.3±4.2	2.1±1.1	11.6±4.1	2.1±1.0	13.7±6.1	7.8±2.1	12.1±8.1	13.3±9.8	13.7±6.1	7.8±2.1
OCI _P	1.1±0.9	0.9±0.3	3.1±1.8	0.7±0.2	1.9±1.2	0.9±0.3	2.3±0.9	1.9±0.9	1.3±0.8	2.1±1.3	2.3±0.9	1.9±0.9
OCL _P	1.8±0.3	1.1±0.1	2.3±1.0	0.9±0.1	1.5±1.0	1.2±0.2	2.7±2.1	1.1±0.5	2.9±3.1	2.2±1.8	2.7±2.1	1.1±0.5
V-L-UT _P	3.2±1.0	2.1±1.3	4.2±1.9	1.2±0.7	4.9±2.1	1.9±1.1	3.6±3.5	2.1±0.3	2.9±2.1	3.2±2.9	3.6±3.5	2.1±0.3
FIB _P	4.1±3.2	1.8±0.9	3.2±2.2	2.1±0.8	12.6±4.3	2.9±1.3	13.3±7.1	1.1±0.7	9.1±7.6	4.7±3.7	13.3±7.1	1.1±0.7

* $\bar{x} \pm s$ = pooled mean values \pm standard deviations

p < 0.001**

† 0.1

 $P < 0.03$

†† $p < 0.25$

†† $P < 0.02$

VARIABLES

- VV: Volumetric density of bone (trabecular bone/total bone) in mm^3/cm^3 .
- SV: Surface density of bone (trabecular bone/total bone) in mm^2/cm^3 .
- D-TRAB: Mean trabecular diameter in microns.
- SV-OB: Surface density of active osteoid covered by osteoblasts in mm^2/cm^3 .
- OBI: Osteoblastic index (number of osteoblasts/ mm^3 of bone).
- OCL%: Fraction of trabecular surface covered by osteoclastic interface (bone osteoclast interface/total trabecular surface) in per cent.
- V-L-TOT: Relative volume density of total resorptive lacunae (volume of total resorptive lacunae/trabecular bone) in per cent.
- OCl: Osteoclastic index (number of osteoclasts/ mm^3).
- FIB %: Fraction of trabecular surface covered by fibers (bone fiber interface/total trabecular surface) in per cent.

LEGENDS

FIGURE 0A. An end-view of the copolymer implant plug magnified 50X in a scanning electron microscope.

FIGURE 0B: The same implant as FIGURE 0A, but magnified 100X. The irregular, spongy morphology of the copolymer may be easily observed.

FIGURE 1. Osseous wound healing in a control site of the tibia of a rat at 28 days.

FIGURE 2A: At 7 days the copolymer implant plug (*) appeared wavy, heterogenous, and amorphous with infrequent lymphocytes and polymorphonuclear cells (arrows).

FIGURE 2B. At 7 days zones of osteoid with robust osteoblasts could be seen.

FIGURE 3. By 14 days within the experimental wound bed the copolymer had broken down into numerous islands (*). Bony trabeculae were evident throughout the dissolving implant (arrows). A bony bridge had also formed (arrowheads). An inflammatory response was not evident.

FIGURE 4: By 21 days numerous bony trabeculae were developed at the implant site and there was scarce evidence of the implant.

FIGURE 5: At 21 days all wound sites treated with an implant had a well developed bony bridge (arrowheads).

FIGURE 6: By 42 days complete obliteration of the osseous defect was achieved (between arrowheads). In several specimens, wound closure was demonstrated at 28 days. No inflammatory infiltrate was present.

REFERENCES

1. D.E. Cutright, E.E. Hunsuck, and J.D. Beasley, III: "Fracture Reducing Using a Biodegradable Material, Polylactic Acid." *J Oral Surg* 29: 393-397 (1971).
2. D.E. Cutright, J.D. Beasley, III, and B. Perez: "Histologic Comparison of Polylactic and Polyglycolic Acid Sutures." *Oral Surg* 32:165-173 (1971).
3. E.J. Frazza and E.E. Schmitt: "A New Absorbable Suture." *J Biomed Mater Res Symposium* 1:43-58 (1971).
4. L. Getter and D.E. Cutright: "Fracture Fixation Using Biodegradable Material." *J Oral Surg* 30:344-348 (1972).
5. D.E. Cutright and E.E. Hunsuck: "The Repair of Fractures of the Orbital Floor." *Oral Surg* 33:28-34 (1972).
6. R.A.J. Olson, D.L. Roberts, and D.B. Osbon: "A Comparative Study of Polylactic Acid, Gelfoam, and Surgicel in Healing Extraction Sites." *Oral Surg* 53:441-449 (1982).
7. J.F. Nelson, H.G. Stanford, and D.E. Cutright: "Evaluation and Comparisons of Biodegradable Substances and Osteogenic Agents." *Oral Surg* 43:836-843 (1977).
8. J.S. Giansanti: "The Pattern and Width of the Collagen Bundles in Bone and Cementum." *Oral Surg* 30:508-514 (1970).
9. D.E. Cutright, B. Perez, J.D. Beasley, III, W.J. Larson, and W.R. Posey: "Degradation Rates of Polymers and Copolymers of Polylactic and Polyglycolic Acids." *Oral Surg* 37:142-152 (1974).

10. R.K. Kulkarni, E.G. Moore, A.F. Hegyeli, and F. Leonard: "Biodegradable Poly(lactic acid) Polymers." *J Biomed Mater Res* 5:169-181 (1971).
11. R.G. Sinclair and G.M.Gynn: *Preparation and Evaluation of Glycolic and Lactic Acid-Based Polymers for Implant Devices Used in Management of Maxillofacial Trauma, Part I.* Final Scientific Report under Contract #DADA17-72-C-1053 by Battelle Columbus Laboratories, Columbus, Ohio supported by U. S. Army Medical Research and Development Command, Washington, D.C. 20314 (1972).




FIG. 8770A




FIG. 8780B



FIG.




FIG. 2 A




FIG. 2B






FIG. 4



FIG. 5



DATE
FILMED
8-8